Objectives: To analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology survey. Methods: A prospective multicenter study performed between 2004 and 2007 at 49 Italian Departments. Results: During the study period 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematologic malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 39%). The most common sites of infection were sinus (35%) with/without CNS involvement, lung alone (25%), skin (20%), but in 11 cases (18%) dissemination was observed. According to the EORTC’s criteria, the diagnosis of zygomycosis was proven in 46 patients (77%) and in most of them it was made in vivo (40/46 patients, 87%); in the remaining 14 cases (23%) the diagnosis was probable. Fifty-one patients received antifungal therapy and in 30 of them surgical debridement was also performed. The most commonly used antifungal drug was liposomal amphotericin B (L-AmB), administered in 44 patients: 36 of these patients (82%) responded to therapy; remarkably all the 7 patients receiving sequential therapy with L-AmB and Posaconazole improved. As a whole it was registered an attributable mortality rate of 32% (19/60), that is reduced to 18% in patients treated with L-AmB (8/44). Conclusions: Zygomycosis is a rare and aggressive filamentous fungal infection, still associated with a high mortality rate. In our study appears an inversion of this trend, with a better prognosis and a mortality significantly lower than that reported in literature. It is possible that new extensive, aggressive diagnostic and therapeutic procedures, such as the use of L-AmB and surgery, could have improved the prognosis of these patients.

Pagano, L., Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology), <<JOURNAL OF CHEMOTHERAPY>>, 2009; 21 (3): 322-329 [http://hdl.handle.net/10807/3825]

Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

Pagano, Livio
2009

Abstract

Objectives: To analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology survey. Methods: A prospective multicenter study performed between 2004 and 2007 at 49 Italian Departments. Results: During the study period 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematologic malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 39%). The most common sites of infection were sinus (35%) with/without CNS involvement, lung alone (25%), skin (20%), but in 11 cases (18%) dissemination was observed. According to the EORTC’s criteria, the diagnosis of zygomycosis was proven in 46 patients (77%) and in most of them it was made in vivo (40/46 patients, 87%); in the remaining 14 cases (23%) the diagnosis was probable. Fifty-one patients received antifungal therapy and in 30 of them surgical debridement was also performed. The most commonly used antifungal drug was liposomal amphotericin B (L-AmB), administered in 44 patients: 36 of these patients (82%) responded to therapy; remarkably all the 7 patients receiving sequential therapy with L-AmB and Posaconazole improved. As a whole it was registered an attributable mortality rate of 32% (19/60), that is reduced to 18% in patients treated with L-AmB (8/44). Conclusions: Zygomycosis is a rare and aggressive filamentous fungal infection, still associated with a high mortality rate. In our study appears an inversion of this trend, with a better prognosis and a mortality significantly lower than that reported in literature. It is possible that new extensive, aggressive diagnostic and therapeutic procedures, such as the use of L-AmB and surgery, could have improved the prognosis of these patients.
Inglese
Pagano, L., Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology), <>, 2009; 21 (3): 322-329 [http://hdl.handle.net/10807/3825]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/3825
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact